RFA-RM-27-001: NIH Director’s Pioneer Award (DP1 Clinical Trial Optional)
Closed
This grant is closed. A newer notice from the same program is forecast: NIH Director's Pioneer Award (DP1 Clinical Trial Optional) (RFA-RM-28-001). Status: Expected deadline September 9, 2027. It is in our archive of National Institutes of Health notices from 2026.
National Institutes of Health offered grants of up to $700,000 (at least $700,000) to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 8 awards worth $8.0 million in total. Applications closed on September 9, 2026.
From the official notice on Grants.gov, last changed June 29, 2026. Checked November 7, 2026.
- Award ceiling$700,000
- Award floor$700,000
- Total funding$8.0 million
- Expected awards8
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeDP1
- Clinical trialsOptional
- DP1, NIH Director's Pioneer Award. Support for an exceptionally creative scientist's high-risk, high-impact ideas. Other open DP1 notices.
Application due dates, page limits and budget limits are set in the notice. Read RFA-RM-27-001 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-RM-28-001 | September 3, 2026 | Expected deadline September 9, 2027 | Forecast |
Key dates
| Posted | June 29, 2026 |
|---|---|
| Deadline | September 9, 2026 |
| Archived by Grants.gov | November 8, 2026 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Past Trans-NIH Research Support awards averaged $1.3 million; this notice allows up to $700,000 per award.
- Most of the program's money (72% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The NIH Director"s Pioneer Award supports individual scientists of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator"s research program or elsewhere. Applications in all topics relevant to the broad mission of NIH are welcome. Research may involve basic, translational, or clinical research. The NIH Director"s Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) program of the NIH Common Fund.
Who has won Trans-NIH Research Support grants before
From fiscal 2021 to 2025, Trans-NIH Research Support (93.310) awarded $5.9 billion across 4,433 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Duke University | North Carolina | 66 | $219 million |
| The Leland Stanford Junior University | California | 104 | $176 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 82 | $154 million |
| The Johns Hopkins University | Maryland | 95 | $152 million |
| Yale Univ | Connecticut | 85 | $149 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, RFA-RM-28-001, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-RM-27-001 still open?
No. It closed on September 9, 2026. A newer notice is forecast: RFA-RM-28-001, expected deadline September 9, 2027.
Who can apply for NIH Director’s Pioneer Award (DP1 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for NIH Director’s Pioneer Award (DP1 Clinical Trial Optional)?
Closed September 9, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $700,000 each. About $8.0 million in total across about 8 awards.
Who has won Trans-NIH Research Support grants before?
The largest recipients over five fiscal years were Duke University, The Leland Stanford Junior University, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 4,433 awards worth $5.9 billion in that time.
Similar open grants
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- NIH Director's Pioneer Award (DP1 Clinical Trial Optional)
- Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)